JY
ODT

Jeff Yass’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Jeff Yass’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,000
Closed -$96K – 13593
2021
Q1 		$96K Sell
28,000
-31,500
-53% -$595K ﹤0.01% 11883
2020
Q4 		$1.14M Buy
59,500
+34,100
+134% +$526K ﹤0.01% 6409
2020
Q3 		$341K Sell
25,400
-14,900
-37% -$422K ﹤0.01% 8454
2020
Q2 		$1.71M Sell
40,300
-18,300
-31% -$592K ﹤0.01% 4789
2020
Q1 		$1.62M Buy
+58,600
New +$1.71M ﹤0.01% 4364

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Jeff Yass's ODT Position: Q4 2021 in Review

Jeff Yass sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 35,475 shares — an estimated $103K sold.

Jeff Yass first reported a position in ODT in Q1 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Jeff Yass reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jeff Yass sold 35,475 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $103K.
  • Jeff Yass first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Jeff Yass's Odonate Therapeutics, Inc. Common Stock position peaked at $1.08M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.